

Remarks:

This is in response to the Official Action of May 24, 2005 for the above-captioned application.


Claims 2-4, 8-10, 12-14, 18, 25, and 28-29 have been rejected under 35 USC 112, second paragraph, as allegedly indefinite.

Purely to expedite prosecution, Applicants have cancelled Claims 4, 10, and 14; amended Claims 18, 25, 29 and 29 in accordance with the Official Action's remarks 4.-7. (pp. 2-3 of the Official Action); and amended Claim 18 to recite "between two and four carbons" instead of "been two and four carbons". The latter amendment is supported by the specification as originally filed and by Claim 18 as originally filed (see, e.g., the recitation of "each (C₁-C₄) alkyl group of said substituents having between two and four carbon atoms..." four lines above the recitation of "been" in Claim 18 as originally filed) and therefore does not constitute new matter. Similarly, all other above amendments, which are in accordance with the Official Action's remarks 4.-7., relate to merely clerical errors and/or are supported by the specification and claims as originally filed, and therefore do not introduce new matter.

In view of the foregoing, allowance of all pending claims in the application is respectfully requested.

Please charge any appropriate fee to cover this submission to Pfizer Deposit Account No. 16-1445. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Date: June 15, 2005

Pfizer, Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898